Drug Discovery Stocks List

Recent Signals

Date Stock Signal Type
2019-11-21 ADPT 20 DMA Support Bullish
2019-11-21 ATHX Bearish Engulfing Bearish
2019-11-21 ATHX Upper Bollinger Band Walk Strength
2019-11-21 BASI Lower Bollinger Band Walk Weakness
2019-11-21 BASI Stochastic Reached Oversold Weakness
2019-11-21 BASI Calm After Storm Range Contraction
2019-11-21 BBC Narrow Range Bar Range Contraction
2019-11-21 BCEL New 52 Week Closing Low Bearish
2019-11-21 BCEL NR7 Range Contraction
2019-11-21 BLFS 20 DMA Resistance Bearish
2019-11-21 BLRX Crossed Above 50 DMA Bullish
2019-11-21 BMRN NR7 Range Contraction
2019-11-21 BNTX Upper Bollinger Band Walk Strength
2019-11-21 BNTX New 52 Week High Strength
2019-11-21 BNTX Spinning Top Other
2019-11-21 BNTX Bearish Engulfing Bearish
2019-11-21 CRIS Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-11-21 CRIS 1,2,3 Retracement Bearish Bearish Swing Setup
2019-11-21 CRL Cup with Handle Other
2019-11-21 DMPI Pocket Pivot Bullish Swing Setup
2019-11-21 GE New 52 Week Closing High Bullish
2019-11-21 GE MACD Bearish Signal Line Cross Bearish
2019-11-21 GLW Lower Bollinger Band Walk Weakness
2019-11-21 GLW Lizard Bullish Bullish Day Trade Setup
2019-11-21 GLW Hammer Candlestick Bullish
2019-11-21 GLYC Volume Surge Other
2019-11-21 GLYC MACD Bearish Signal Line Cross Bearish
2019-11-21 GLYC Fell Below 20 DMA Bearish
2019-11-21 GLYC 50 DMA Support Bullish
2019-11-21 GLYC New Downtrend Bearish
2019-11-21 GNMX 20 DMA Resistance Bearish
2019-11-21 GNMX Bollinger Band Squeeze Range Contraction
2019-11-21 HTGC Fell Below 20 DMA Bearish
2019-11-21 IDYA Calm After Storm Range Contraction
2019-11-21 IDYA NR7 Range Contraction
2019-11-21 IEX 20 DMA Support Bullish
2019-11-21 IEX 50 DMA Support Bullish
2019-11-21 INFI Stochastic Reached Overbought Strength
2019-11-21 INFI 50 DMA Support Bullish
2019-11-21 IONS Stochastic Reached Overbought Strength
2019-11-21 IONS Upper Bollinger Band Walk Strength
2019-11-21 LXRX MACD Bullish Signal Line Cross Bullish
2019-11-21 LXRX Spinning Top Other
2019-11-21 MREO Slingshot Bearish Bearish Swing Setup
2019-11-21 MREO Pocket Pivot Bullish Swing Setup
2019-11-21 MREO Shooting Star Candlestick Bearish
2019-11-21 MREO 20 DMA Resistance Bearish
2019-11-21 PKI 200 DMA Support Bullish
2019-11-21 PKI Upper Bollinger Band Walk Strength
2019-11-21 PRTA Upper Bollinger Band Walk Strength
2019-11-21 SMMT 200 DMA Resistance Bearish
2019-11-21 SMMT Narrow Range Bar Range Contraction
2019-11-21 SMMT Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-11-21 SRRA New 52 Week Low Weakness
2019-11-21 STRO Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2019-11-21 STRO MACD Bearish Signal Line Cross Bearish
2019-11-21 STRO 1,2,3 Pullback Bullish Bullish Swing Setup
2019-11-21 STRO Spinning Top Other
2019-11-21 STRO 200 DMA Support Bullish
2019-11-21 STRO Fell Below 20 DMA Bearish
2019-11-21 SUPN Shooting Star Candlestick Bearish
2019-11-21 TWST Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-11-21 UMRX New 52 Week Closing Low Bearish
2019-11-21 UMRX New Downtrend Bearish
2019-11-21 UMRX Lower Bollinger Band Walk Weakness
2019-11-21 UMRX New 52 Week Low Weakness
2019-11-21 VTGN Narrow Range Bar Range Contraction
2019-11-21 VTGN Calm After Storm Range Contraction
2019-11-21 WAT 50 DMA Resistance Bearish
2019-11-21 WAT Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-11-21 WAT Stochastic Sell Signal Bearish

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered through identifying the active ingredient from traditional remedies or by serendipitous discovery. Later chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that have a desirable therapeutic effect in a process known as
classical pharmacology. Since sequencing of the human genome which allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compounds libraries against isolated biological targets which are hypothesized to be disease modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy.
Modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, it will begin the process of drug development prior to clinical trials. One or more of these steps may, but not necessarily, involve computer-aided drug design. Modern drug discovery is thus usually a capital-intensive process that involves large investments by pharmaceutical industry corporations as well as national governments (who provide grants and loan guarantees). Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, "expensive, difficult, and inefficient process" with low rate of new therapeutic discovery. In 2010, the research and development cost of each new molecular entity was about US$1.8 billion. Drug discovery is done by pharmaceutical companies, with research assistance from universities. The "final product" of drug discovery is a patent on the potential drug. The drug requires very expensive Phase I, II and III clinical trials, and most of them fail. Small companies have a critical role, often then selling the rights to larger companies that have the resources to run the clinical trials.
Discovering drugs that may be a commercial success, or a public health success, involves a complex interaction between investors, industry, academia, patent laws, regulatory exclusivity, marketing and the need to balance secrecy with communication. Meanwhile, for disorders whose rarity means that no large commercial success or public health effect can be expected, the orphan drug funding process ensures that people who experience those disorders can have some hope of pharmacotherapeutic advances.

More about Drug Discovery